Meeting
2019 ASCO Annual Meeting
A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) in older patients using fludarabine and total body irradiation (Flu/TBI).
Authors
Omer Hassan JAMY
University of Alabama at Birmingham, Birmingham, AL
Omer Hassan JAMY , Donna E. Salzman , Antonio Di Stasi , Racquel Innis-Shelton , Costa Luciano , Lawrence S. Lamb Jr., Shin Mineishi , Ayman A. Saad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogenic Stem Cell Transplantation
Clinical Trial Registration Number
NCT01991457
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7069)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7069
Abstract #
TPS7069
Poster Bd #
440a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Low-toxic myeloablative conditioning regimen in haploidentical hematopietic stem cell transplantation for elderly patients with acute myeloid leukemia.
First Author: Cynthia Aristei
Poster
2011 ASCO Annual Meeting
A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.
First Author: S. Kim
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat
Poster
2022 ASCO Annual Meeting
Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
First Author: Alison Sehgal